Trials / Recruiting
RecruitingNCT06850038
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
Prospective Registry-Based Study Evaluating the Effectiveness and Safety of Odevixibat in Participants With Alagille Syndrome (ALGS)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study will collect information from patients with Alagille syndrome (ALGS) as they use odevixibat (Bylvay) in their daily lives. Odevixibat is a medicine that helps patients with ALGS, a rare disease that harms their liver and causes itching. The main aim of this study is to observe the long-term, everyday effectiveness and safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.
Conditions
Timeline
- Start date
- 2025-04-22
- Primary completion
- 2029-11-01
- Completion
- 2029-11-01
- First posted
- 2025-02-27
- Last updated
- 2026-04-01
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06850038. Inclusion in this directory is not an endorsement.